Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients

Endocrine

Volumn 49, Issue 2, 2015, Pages 528-537

  Bañón, Sara ^a   Rosillo, Marta ^a   Gómez, Ana ^a   Pérez Elias, María J ^a   Moreno, Santiago ^a   Casado, José Luis ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Calcidiol; HIV; Parathyroid hormone; Supplementation; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; CALCIFEDIOL; CALCIUM; PARATHYROID HORMONE; 25-HYDROXYVITAMIN D; VITAMIN; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEASONAL VARIATION; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BLOOD; COMORBIDITY; HIV INFECTIONS; HYPERPARATHYROIDISM, SECONDARY; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; CALCIFEDIOL; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS; YOUNG ADULT;

EID: 84929951104     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0489-2     Document Type: Article

References (42)

1. A.L. Willig, E.T. Overton, Metabolic consequences of HIV: pathogenic insights. Curr. HIV/AIDS Rep. 11(1), 35–44 (2014). doi:10.1007/s11904-013-0191-7
2. C.N. Dao, P. Patel, E.T. Overton, F. Rhame, S.L. Pals, C. Johnson, T. Bush, J.T. Brooks, Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin. Infect. Dis. 52(3), 396–405 (2011). doi:10.1093/cid/ciq158
3. O.M. Adeyemi, D. Agniel, A.L. French, P.C. Tien, K. Weber, M.J. Glesby, M.C. Villacres, A. Sharma, D. Merenstein, E.T. Golub, W. Meyer, M. Cohen, Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J. Acquir. Immune Defic. Syndr. 57(3), 197–204 (2011). doi:10.1097/QAI.0b013e31821ae418
4. M. Cervero, J.L. Agud, C. Garcia-Lacalle, V. Alcazar, R. Torres, J.J. Jusdado, S. Moreno Guillen, Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. AIDS Res. Hum. Retrovir 28(9), 963–971 (2012). doi:10.1089/AID.2011.0244
5. B. Terrier, F. Carrat, G. Geri, S. Pol, L. Piroth, P. Halfon, T. Poynard, J.C. Souberbielle, P. Cacoub, Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J. Hepatol. 55(4), 756–761 (2011). doi:10.1016/j.jhep.2011.01.041
6. T.T. Brown, G.A. McComsey, Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 15(3), 425–429 (2010). doi:10.3851/IMP1502
7. Van Den Bout-Van, C.J. Den Beukel, L. Fievez, M. Michels, F.C. Sweep, A.R. Hermus, M.E. Bosch, D.M. Burger, B. Bravenboer, P.P. Koopmans, A.J. Van Der Ven, Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retrovir 24(11), 1375–1382 (2008). doi:10.1089/aid.2008.0058
8. H.A. Bischoff-Ferrari, A. Shao, B. Dawson-Hughes, J. Hathcock, E. Giovannucci, W.C. Willett, Benefit-risk assessment of vitamin D supplementation. Osteoporos. Int. 21(7), 1121–1132 (2010). doi:10.1007/s00198-009-1119-3
9. K.C. Chiu, A. Chu, V.L. Go, M.F. Saad, Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 79(5), 820–825 (2004)
10. D.J. Llewellyn, K.M. Langa, I.A. Lang, Serum 25-hydroxyvitamin D concentration and cognitive impairment. J. Geriatr. Psychiatry Neurol. 22(3), 188–195 (2009). doi:10.1177/0891988708327888
11. E.T. Overton, M.T. Yin, The rapidly evolving research on vitamin D among HIV-infected populations. Curr Infect Dis Rep 13(1), 83–93 (2011). doi:10.1007/s11908-010-0144-x
12. S. Mehta, E. Giovannucci, F.M. Mugusi, D. Spiegelman, S. Aboud, E. Hertzmark, G.I. Msamanga, D. Hunter, W.W. Fawzi, Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE 5(1), e8770 (2010). doi:10.1371/journal.pone.0008770
13. J.P. Viard, J.C. Souberbielle, O. Kirk, J. Reekie, B. Knysz, M. Losso, J. Gatell, C. Pedersen, J.R. Bogner, J.D. Lundgren, A. Mocroft, Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 25(10), 1305–1315 (2011). doi:10.1097/QAD.0b013e328347f6f7
14. C.K. Kwan, B. Eckhardt, J. Baghdadi, J.A. Aberg, Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retrovir 28(9), 1025–1032 (2012). doi:10.1089/AID.2011.0325
15. J.L. Casado, S. Banon, R. Andres, M.J. Perez-Elias, A. Moreno, S. Moreno, Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int 25(3), 1071–1079 (2014). doi:10.1007/s00198-013-2506-3
16. Martinez, E., Jodar Gimeno, E., Reyes Garcia, R., Carpintero, P., Casado, J.L., Del Pino Montes, J., Domingo Pedrol, P., Estrada, V., Maalouf, J., Negredo, E., Ocampo, A., Munoz-Torres, M.: [Consensus statement: Recommendations for the management of metabolic bone disease in human immunodeficiency virus patients.]. Enfermedades infecciosas y microbiologia clinica (2013). doi:10.1016/j.eimc.2013.07.008
17. C. del Rio, Updated antiretroviral treatment guidelines from DHHS and EACS. AIDS Clin. Care 20(1), 7 (2008)
18. G. Dragovic, D. Jevtovic, Report on the 13th European AIDS conference/EACS. Vojnosanitetski pregled. Milit Med Pharm Rev 69(1), 98–99 (2012)
19. Rigueira Garcia, A.I.: [Recommendations on vitamin D and calcium supplements for adults in Spain]. Rev Esp Salud Publica 86(5), 461–482 (2012). doi:10.4321/S1135-57272012000500002
20. Torregrosa, J.V., Bover, J., Cannata Andia, J.: Spanish society of nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Introduction. Nefrologia 31(Suppl 1), 1–2 (2011). doi:10.3265/Nefrologia.pre2011.Jan.10815
21. M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, M.H. Murad, C.M. Weaver, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7), 1911–1930 (2011). doi:10.1210/jc.2011-0385
22. C.J. Rosen, J.C. Gallagher, The 2011 IOM report on vitamin D and calcium requirements for north america: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 14(2), 79–84 (2011). doi:10.1016/j.jocd.2011.03.004
23. S.J. Silverberg, E.M. Lewiecki, L. Mosekilde, M. Peacock, M.R. Rubin, Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2), 351–365 (2009). doi:10.1210/jc.2008-1760
24. A.K. Kasahara, R.J. Singh, A. Noymer, Vitamin D (25OHD) serum seasonality in the United States. PLoS ONE 8(6), e65785 (2013). doi:10.1371/journal.pone.0065785
25. M.F. Holick, E.S. Siris, N. Binkley, M.K. Beard, A. Khan, J.T. Katzer, R.A. Petruschke, E. Chen, A.E. de Papp, Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90(6), 3215–3224 (2005). doi:10.1210/jc.2004-2364
26. P.L. Havens, C.B. Stephensen, R. Hazra, P.M. Flynn, C.M. Wilson, B. Rutledge, J. Bethel, C.G. Pan, L.R. Woodhouse, M.D. Van Loan, N. Liu, J. Lujan-Zilbermann, A. Baker, B.G. Kapogiannis, K. Mulligan, Adolescent Medicine trials network for, H.I.V.A.I.s.t.: Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 54(7), 1013–1025 (2012). doi:10.1093/cid/cir968
27. V. Giacomet, A. Vigano, V. Manfredini, C. Cerini, G. Bedogni, S. Mora, M. Borelli, D. Trabattoni, G.V. Zuccotti, Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials 14(2), 51–60 (2013). doi:10.1310/hct1402-51
28. C.T. Longenecker, C.O. Hileman, T.L. Carman, A.C. Ross, S. Seydafkan, T.T. Brown, D.E. Labbato, N. Storer, V. Tangpricha, G.A. McComsey, Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther 17(4), 613–621 (2012). doi:10.3851/IMP1983
29. R.J. Piso, M. Rothen, J.P. Rothen, M. Stahl, C. Fux, Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients. BMC Infect. Dis. 13, 577 (2013). doi:10.1186/1471-2334-13-577
30. L. Tripkovic, H. Lambert, K. Hart, C.P. Smith, G. Bucca, S. Penson, G. Chope, E. Hypponen, J. Berry, R. Vieth, S. Lanham-New, Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am. J. Clin. Nutr. 95(6), 1357–1364 (2012). doi:10.3945/ajcn.111.031070
31. M. Etminani-Esfahani, H. Khalili, S. Jafari, A. Abdollahi, S. Dashti-Khavidaki, Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz. BMC Res Notes 5, 204 (2012). doi:10.1186/1756-0500-5-204
32. K.D. Cashman, K.M. Seamans, A.J. Lucey, E. Stocklin, P. Weber, M. Kiely, T.R. Hill, Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am. J. Clin. Nutr. 95(6), 1350–1356 (2012). doi:10.3945/ajcn.111.031427
33. H.A. Bischoff-Ferrari, B. Dawson-Hughes, E. Stocklin, E. Sidelnikov, W.C. Willett, J.O. Edel, H.B. Stahelin, S. Wolfram, A. Jetter, J. Schwager, J. Henschkowski, A. von Eckardstein, A. Egli, Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res 27(1), 160–169 (2012). doi:10.1002/jbmr.551
34. N.E. Cusano, S.J. Silverberg, J.P. Bilezikian, Normocalcemic primary hyperparathyroidism. J Clin Densitom 16(1), 33–39 (2013). doi:10.1016/j.jocd.2012.12.001
35. S.J. Silverberg, B.L. Clarke, M. Peacock, F. Bandeira, S. Boutroy, N.E. Cusano, D. Dempster, E.M. Lewiecki, J.M. Liu, S. Minisola, L. Rejnmark, B.C. Silva, M.D. Walker, J.P. Bilezikian, Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99(10), 3580–3594 (2014). doi:10.1210/jc.2014-1415
36. M.F. Holick, Vitamin D deficiency. N. Engl. J. Med. 357(3), 266–281 (2007). doi:10.1056/NEJMra070553
37. G. Jones, Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88(2), 582S–586S (2008)
38. A. Conesa-Botella, E. Florence, L. Lynen, R. Colebunders, J. Menten, R. Moreno-Reyes, Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 7, 40 (2010). doi:10.1186/1742-6405-7-40
39. J. Fox, B. Peters, M. Prakash, J. Arribas, A. Hill, C. Moecklinghoff, Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res. Hum. Retrovir 27(1), 29–34 (2011). doi:10.1089/aid.2010.0081
40. T. Welz, K. Childs, F. Ibrahim, M. Poulton, C.B. Taylor, C.F. Moniz, F.A. Post, Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 24(12), 1923–1928 (2010). doi:10.1097/QAD.0b013e32833c3281
41. P.L. Havens, K. Mulligan, R. Hazra, P. Flynn, B. Rutledge, M.D. Van Loan, J. Lujan-Zilbermann, B.G. Kapogiannis, C.M. Wilson, C.B. Stephensen, Adolescent Medicine Trials Network for, H.I.V.A.I.S.T.: Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab 97(11), 4004–4013 (2012). doi:10.1210/jc.2012-2600
42. K. Rajakumar, J.D. Fernstrom, M.F. Holick, J.E. Janosky, S.L. Greenspan, Vitamin D status and response to Vitamin D(3) in obese vs. non-obese African American children. Obesity 16(1), 90–95 (2008). doi:10.1038/oby.2007.23